Personalis (PSNL) Reports Q4 Loss, Tops Revenue Estimates

Company Performance - Personalis reported a quarterly loss of $0.23 per share, better than the Zacks Consensus Estimate of a loss of $0.25, and an improvement from a loss of $0.46 per share a year ago, representing an earnings surprise of 8% [1] - The company posted revenues of $16.8 million for the quarter ended December 2024, slightly surpassing the Zacks Consensus Estimate by 0.06%, but down from $19.68 million in the same quarter last year [2] - Over the last four quarters, Personalis has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] Stock Outlook - Personalis shares have declined approximately 22.5% since the beginning of the year, contrasting with the S&P 500's gain of 1.3% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.26 on revenues of $15.22 million, and for the current fiscal year, it is -$0.99 on revenues of $85.13 million [7] - The estimate revisions trend for Personalis is currently unfavorable, resulting in a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [6] Industry Context - The Medical - Generic Drugs industry, to which Personalis belongs, is currently ranked in the bottom 22% of over 250 Zacks industries, suggesting a challenging environment [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Personalis's stock performance [5]